Horizon And Arrowhead To Develop RNAi Therapeutic For Gout

Target Is Xanthine Dehydrogenase, Primary Source Of Serum Uric Acid

Gout Pact Will Give Arrowhead $40m upfront • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapy Areas